The Phase III ETHOS trial for AstraZeneca's budesonide, glycopyrronium and formoterol fumarate, 320/14.4/9.6mcg (Breztri Aerosphere) combination therapy, formerly known as PT010, has demonstrated positive results for patients with moderate to severe chronic obstructive pulmonary disease (COPD).1

The 52-week ETHOS trial assesses the efficacy and safety of this triple combination in symptomatic patients. The randomized, double-blinded study involves more than 8500 patients who have experienced moderate to severe exacerbation in the previous year, as well as patients receiving at least 2 inhaled maintenance treatments before beginning the trial.1

The participants were randomly assigned to one of four groups, receiving either glycopyrronium-formoterol fumarate (Bevespi Aerosphere), budesonide-formoterol fumarate (Symbicort), or the triple-combination therapy. All the therapies are administered using a pressurized metered-dose inhaler (pMDI).2

The budesonide-glycopyrronium-formoterol fumarate combination is composed of inhalable corticosteroid budesonide and 2 bronchodilators. In most recent results, the standard dose of this therapy was shown to effectively reduce episodes of exacerbation stemming from COPD compared to 2 other existing therapies. The triple-combination is also demonstrated to be as safe and tolerable as the other 2 approved dual-combination therapies.2

COPD is a progressive disease that affects around 384 million people worldwide and is predicted to be the third leading cause of death by 2020.1

  1. Breztri Aerosphere Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease [news release]. AstraZeneca media room; August 28, 2019. Accessed September 5, 2019.
  2. Breztri Aerosphere Reduced COPD Exacerbations Better Than Approved Therapies, Phase 3 Trial Shows. COPD News Today website. Published August 30, 2019. Accessed September 5, 2019.